Helen Dakin
Colleges
Helen Dakin
MSc DPhil
Associate Professor
Helen Dakin is a health economist specialising in assessing the cost-effectiveness of healthcare interventions. Her research interests include methods for trial and model-based economic evaluation, with particular focus on uncertainty, interacting healthcare decisions and factorial trials.
Helen co-leads the Patient Reported Outcomes and Health Economics module of the MSc in Clinical Trials and leads the Health Economics Research Centre (HERC) online short course Integrating Economic Evaluation into Clinical Trials.
Helen has led and collaborated on the health economic analyses of numerous randomised controlled trials, models and observational studies. Projects include: the KAT trial, which assesses the cost-effectiveness of different types of knee replacement component; the STAR trial, which evaluates radiotherapy alongside ranibizumab (Lucentis) in age-related macular degeneration; and the Supporting Women with adhErence to adjuvant Endocrine Therapy following breast cancer (SWEET) trial.
Helen joined HERC in February 2008. In 2014, she completed a DPhil at the University of Oxford on the optimal methods for conducting economic evaluations of factorial clinical trials. She previously worked at Abacus International and completed her MSc in Economic Evaluation in Healthcare at City University. She graduated from Cambridge University with Masters and Bachelor's degrees in Biochemistry.
Recent publications
-
How are maternal and fetal outcomes incorporated when measuring benefits of interventions in pregnancy? Findings from a systematic review of cost-utility analyses.
Abel L. et al, (2024), Health and Quality of Life Outcomes
-
Using QALYs as an outcome for assessing global prediction accuracy in diabetes simulation models
DAKIN H. et al, (2024), Medical decision making
-
Using orthopaedic health care resources efficiently: A cost analysis of day surgery for unicompartmental knee replacement.
Hlatshwako TG. et al, (2024), Knee, 49, 147 - 157
-
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management.
Gao N. et al, (2024), Pharmacoeconomics
-
Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial.
Jackson TL. et al, (2024), Lancet